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Background: Bordetella bronchiseptica is a common pathogenic or colonizing organism of domestic mammals. In dogs, it causes an infectious
tracheobronchitis known as Kennel Cough. Human infections are unusual and almost exclusively described in immunocompromised patients who
have had contact with a known animal reservoir. It is rarely reported in Cystic Fibrosis (CF), possibly hampered by low recovery from culture and
organism misidentiﬁcation. We describe the incidence and characteristics of B. bronchiseptica in our CF population.
Methods: A retrospective cohort study was conducted of our center's CF patient population. Patients were included if they had B. bronchiseptica
isolated on one or more occasion.
Results: Seven children with CF isolated B. bronchiseptica on 23 occasions, frequently associated with the symptoms of a pulmonary exacerbation.
Four patients required hospitalization.
Conclusion: These results suggest that B. bronchiseptica may be more common than previously reported and may play a potential pathogenic role
in CF.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Bordetella bronchiseptica; Pathogen; Animal; Cystic Fibrosis1. Introduction
Bordetella bronchiseptica is a gram-negative medium sized
rod, that was first described by Ferry [1] in 1910 as the veterinary
pathogen responsible for respiratory disease in a wide range of
mammals including dogs, horses, rabbits, swine, rodents and
cats. In dogs, it causes an infectious tracheobronchitis commonly
known as “kennel cough”. B. bronchiseptica is a major cause of
snuffles in rabbits, pneumonia in cats, and atrophic rhinitis in
piglets [1,2]. It has been identified as a respiratory pathogen in
horses [3]. Infection with this organism can lead to chronic and
asymptomatic colonization in animals which may persist in the
upper respiratory tract indefinitely [4,5].☆ Presented at the North American Cystic Fibrosis Conference, November 3& 4,
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http://dx.doi.org/10.1016/j.jcf.2013.08.002B. bronchiseptica is rarely associated with human disease
but has been reported as a cause of pertussis-like disease [2].
B. bronchiseptica and Bordetella pertussis are closely related
species that exhibit little genetic variation [2,6]. B. pertussis,
the causative agent of whooping cough, is strictly a human
pathogen. Analysis of the genomic sequences indicates that
B. pertussis evolved from a B. bronchiseptica-like ancestor as a
human-adapted lineage. Human adaptation appears to be a
consequence of gene deletions and the disease severity is
related to loss of gene regulatory functions [6]. Both strains
have virulence factors in common which are regulated by the
complex Bordetella virulence gene (BvgAS). BvgAS is a
two-component signal transduction system which responds to
certain environmental conditions as Bordetella travels within
and between mammalian hosts [7]. Except for the pertussis
toxin, B. bronchiseptica produces nearly all the factors
associated with B. pertussis virulence. Expressed virulence
factors exist in three different phases: a virulent Bvg+ phase, a
non-virulent Bvg− phase and an intermediate Bvgi phase that isby Elsevier B.V. All rights reserved.
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necessary for respiratory tract colonization characterized by
the expression of adhesions, autotransporters and toxins.
Adhesions and autotransporters, such as filamentous hemag-
glutinin (FHA), fimbriae, and pertactin, help the organisms
adhere to the cilia of respiratory epithelial cells resulting in
stasis of the cilia and difficulty clearing mucus secretions [5].
Adenylate cyclase toxin (CyaA), also expressed in the Bvg+
phase, interferes with the host immune response allowing the
organisms to grow to higher numbers and persist longer in the
respiratory tract [8]. Studies using phase-locked mutants have
determined that the Bvg+ phase was sufficient for respiratory
colonization and infection [7,9]. The non-virulent Bvg− phase
is characterized by motility in B. bronchiseptica and is required
for survival outside of the host in nutrient-limiting conditions
suggesting an environmental reservoir [2,7]. Although never
proven, the Bvgi phase may be important in aerosol
transmission of B. bronchiseptica between hosts [7,9,10].
Several studies have tried to provide an explanation for the
long-term persistence of B. bronchiseptica in the mammalian
host. A frequent hypothesis to explain continued persistent
infection or asymptomatic carriage is that these organisms exist
as biofilms [5,11]. The role of biofilm formation in pathogenesis
has been linked to chronic bacterial infections such as CF lung
disease caused by Pseudomonas aeruginosa, a disease that has
become widely accepted as a biofilm-like infection [12]. Irie et al.
investigated B. bronchiseptica virulence factors in relationship
with biofilm formation, determining that the expression of FHA
was required to obtain maximal biofilm formation in the Bvgi
phase in vitro and was primarily phase specific. They further
showed that CyaA, when interacted with FHA in the Bvg+
phase, suppressed biofilm formation suggesting different require-
ments for acute versus persistant infection [5,12]. This was
a slight variance from the study performed by Mishra et al.,
showing robust biofilm formation in both the Bvg+ and Bvgi
phases [11]. Although there were different conclusions, both
studies were in agreement that the BvgAS system was important
in the regulation of biofilm formation [11]. Since then, Sloan
et al. examined the nasal tissue from mice infected with
B. bronchiseptica. They were able to demonstrate biofilms
adherent to the nasal epithelium having similar characteristics to
biofilms formed in vitro on abiotic surfaces. From this data, they
suggested a possible role of biofilms in human infection [13,14].
Histopathology findings from explant tissue infected with
B. bronchiseptica and B. pertussis and tissue biopsies of pertussis
patients have shown damage to the ciliated epithelial cells with
masses of extracellular bacteria in the cilia, structures suggestive
of biofilms [15–17]. The pathology findings along with studies
demonstrating biofilm formation in mice further support the
hypothesis of biofilm mode of existence.
Despite frequent contact with domestic animals, the infection
caused by B. bronchiseptica rarely has been reported in humans
[18,19]. Literature review yields only case reports typically of
immune-compromised patients who had contact with domestic
animal(s) known to harbor B. bronchiseptica. B. bronchiseptica
has been reported in patients with HIV/AIDS [20], cancer [21],
transplants [22,23], and the elderly [24]. In addition, cases ofB. bronchiseptica were reported in patients with other conditions
including trauma [25], hemodialysis [26,27], Sickle Cell Disease
and Down syndrome [28]. Cases of immune-competent patients
contracting B. bronchiseptica have been reported on rare
occasion [29], as have reports of persistent infections [30].
Reports of B. bronchiseptica in CF are extremely rare. Ner
et al. reported four cases in CF patients, two of which were
recent lung transplant recipients, and presumed to be immune
compromised [31]. In their control population of 532 CF
patients, only two cases were found (0.04%). Wallet et al. [32]
reported a 27-year-old woman with CF who, after isolation of
B. bronchiseptica from sputum, suffered a major decline in
lung function over two years. In Wernli's 15 year retrospective
review of B. bronchiseptica isolates from a single institution, 2
of 8 isolates were from patients with CF [19]. Register et al.
described isolation of B. bronchiseptica in an 11 year old
patient with CF who had domestic exposure to a kitten with
an acute respiratory illness. Genetic characterization of the
organism implied feline to human transmission [33]. The
Burkholderia cepacia Research Laboratory and Repository
(BcRLR) evaluated 874 CF respiratory tract isolates, identify-
ing Bordetella spp. (5%) from 43 patients [34]. Based on 16S
ribosomal DNA sequence data, 23 Bordetella spp. isolates
were identified as B. bronchiseptica/parapertussis. All isolates
had been assessed using a phenotypic commercial identifica-
tion system prior to submission by the referring laboratories.
BcRLR analysis of the 43 Bordetella isolates revealed that
only 25% (n = 11) were correctly identified by the referring
laboratories with the remainder misidentified or unidentified
[34,35].
Overgrowth bymore commonCF pathogens includingmucoid
P. aeruginosa, may conceal lower numbers of B. bronchiseptica
making isolation technically challenging. We hypothesize that
B. bronchiseptica may be more common than previously
described in patients with CF due to difficulties with isolation
and accurate identification. In addition, we postulate that
B. bronchiseptica may be associated with or without the
symptoms of a pulmonary exacerbation in patients with
CF. The aim of this study is to describe the frequency of
B. bronchiseptica isolation, the circumstances, the symptoms
associated with isolation of B. bronchiseptica, and the antimicro-
bial sensitivities of the organism in our CF center's patient
population.
2. Methods
2.1. Study design
A retrospective review was conducted of the Children's
Hospitals and Clinics of Minnesota's CF center between 1991
and 2012 following approval from our Institutional Review
Board (IRB). Patients were included if they had a positive
airway culture for B. bronchiseptica from the hospital
laboratory, and a diagnosis of Cystic Fibrosis confirmed by
sweat chloride values N60 mEq/L measured by quantitative
pilocarpine iontophoresis and/or genetic testing positive for 2
known CF-causing mutations. The study period was defined as
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after the last isolate of Bordetella. Records from the Children's
Hospitals and Clinics of Minnesota and Children's Respiratory
and Critical Care Specialists were reviewed for demographics,
diagnoses, lung function, nutritional status, and exposure to
domestic animals. In addition, data were collected for previous or
concurrent airway cultures, sensitivities, signs and symptoms
of pulmonary exacerbations, hospitalizations, treatment, and
response to therapy. Fuchs [36] criteria was applied to identify
signs and symptoms of pulmonary exacerbations including
decline in FEV1, new onset cough, shortness of breath, sputum
production, wheezing, crackles, chest x-ray changes, and weight
loss. For the purpose of this study, the baseline FEV1 was
determined as the best FEV1% predicted within one year prior to
the isolation of B. bronchiseptica.
2.2. Statistical methods
Descriptive statistics were used to describe the characteristics
of the study population. Quantitative variables are expressed as
mean, median and range. To estimate prevalence during the study
periods, the registry data from PortCF and the Epidemiological
Study of Cystic Fibrosis (ESCF) were reviewed to quantify the
number of active patients with CF that were receiving care at our
institution.
2.3. Laboratory isolation and identification
Respiratory specimens were submitted to the laboratory
for patients with CF during routine or episodic encounters.
The samples were plated on a combination of selective and
non-selective agar plates and incubated according to the
recommendations taken from the Cystic Fibrosis Foundation
consensus report [37–39]. B. bronchiseptica is a glucose
non-fermentative rod which has simple nutritional require-
ments, growing in 1–2 days on common laboratory media
such as 5% sheep blood and MacConkey agar. Phenotypic
identification was performed using a commercial biochemical
system, Vitek (bioMèrieux), on all suspicious isolates includ-
ing conventional biochemicals when necessary. Vitek was
unable to identify one isolate, which was subsequently
misidentified as Cupriavidus pauculus (formerly CDC group
IVc-2) by Siemens MicroScan due to a similar phenotypic
profile.
3. Results
Available registry data during the study period reflected a
growing CF center. The pediatric CF center had an ESCF
enrollment of 59 patients in 2002 and 137 patients enrolled in
PortCF in 2012. Seven patients with a median age of 12 years
(range: 1–20) with CF had B. bronchiseptica isolated in airway
cultures on 23 occasions. Four patients grew B. bronchiseptica
once, and three on multiple occasions. All patients had at least
one copy of the most common CF causing mutation,ΔF508, and
5 were homozygous for ΔF508. All 7 patients had documented
exposure to domestic animals known to harbor B. bronchiseptica(Table 1) and the majority of patients 4/7 (57%) either lived on a
farm or operated a kennel on the home property (Table 1). None
of our patients were transplant recipients and none had any other
diagnosis known to impart immune deficiency. All patients had
mild CF lung disease at baseline. Of those able to perform routine
spirometry, the median FEV1 was 99% predicted (range 79–
121% predicted). Based on the study range of PortCF registrants,
the estimated prevalence in our population could range from 5 to
12%.
3.1. Signs and symptoms at time of initial
B. bronchiseptica isolation
All patients experienced an increased cough and 86% (6/7)
had additional signs and symptoms of a pulmonary exacerba-
tion such as decrease in FEV1 and chest x-ray changes when
B. bronchiseptica was first isolated from airway cultures
(Table 2). One patient exhibited a pattern of cough different
from previous pulmonary exacerbations of CF, which was
clinically similar to B. pertussis infection. Two patients were
exposed to animals with a veterinarian-diagnosed case of “kennel
cough”.
3.2. Intercurrent microorganisms
All patients had positive cultures for methicillin-sensitive
Staphylococcus aureus (MSSA) within the year preceding, or
concurrent with the time of B. bronchiseptica isolation. One
patient had intermittent colonization of methicillin-resistant
S. aureus (MRSA). None of our patients had historic isolation
of P. aeruginosa (mucoid) from airway cultures. Three patients
isolated P. aeruginosa (matte) intermittently.
3.3. Antibiotic sensitivity
Fifteen of the 23 B. bronchiseptica isolates had antibiotic
sensitivities reported by the lab. Although antibiotic sensitiv-
ities and treatment for B. bronchiseptica infection varied, most
isolates were resistant to common beta lactam antibiotics
(Table 3).
3.4. Patient outcomes
All symptomatic patients were treated with antibiotics based
on available sensitivity data. Piperacillin/tazobactam, trimeth-
oprim/sulfa, ciprofloxacin, and meropenem were the most
frequently used antibiotics in our patient population. Patient #4,
who had B. bronchiseptica isolated on 13 occasions, has a sulfa
allergy (Table 3).
Four patients were hospitalized for pulmonary exacerbations
coincident with B. bronchiseptica isolation. B. bronchiseptica
and MSSA were present concomitantly in airway cultures in all
four patients. These patients had historically grown MSSA
while asymptomatic and continued to have positive cultures for
MSSA following treatment of B. bronchiseptica and resolution
of symptoms. While patients responded favorably to treatment
directed at B. bronchiseptica, four patients had recurrence and
Table 1
Patient characteristics.
Patient Genetics Sweat
chloride
mEq/L
Gender Age (years) at
first isolate
Number of
isolate events
Baseline
FEV1% predicted
a
Concurrent airway isolates Animal contact
1 DeltaF508/DeltaF508 84/84 F 1.9 2 N/A b MSSA, B. bronchiseptica Dog
2 DeltaF508/DeltaF508 103/111 M 4 1 N/A b B. bronchiseptica, MSSA,
P. aeruginosa (matte)
Dogs,
horses cats,
guinea
pigs/farm
3 DeltaF508/DeltaF508 N/A c F 8 1 87 B. bronchiseptica, MSSA,
group A
streptococci,
Stenotrophomonas maltophilia
Dogs, cats
4 DeltaF508/Delta I507 113 F 12 14 98 B. bronchiseptica
(previously misidentified
as Cupriavidus pauculus), MSSA
Dog with
“kennel cough”,
horses/small farm
5 DeltaF508/DeltaF508 108 F 13 1 79 B. bronchiseptica, P. aeruginosa
(matte), MSSA
Dogs, cats
6 DeltaF508/unknown 90 F 14 2 121 B. bronchiseptica, MSSA, yeast Dogs
(ill)/kennel business
7 DeltaF508/DeltaF508 N/A c M 20 2 112 B. bronchiseptica, MSSA, yeast Dog/farm
a Best FEV1% Predicted value one year prior to first B. bronchiseptica culture.
b Patient too young to perform PFTs.
c Data not available from institutional record.
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have recommended vaccination of the pets but this has not been
accomplished. Three of our patients lived on small farms and
had exposure to multiple animal reservoirs. One patient's
family operated a kennel.
4. Discussion
In our CF center, the majority of B. bronchiseptica isolates
have been associated with the CF population. All patients had
contact with a known domestic animal reservoir. Those who
live in rural environments with exposure to multiple animals
may be at more risk. We speculate that the CF lung with its
impaired host defense including impaired mucus clearance,
and ciliary dysfunction may selectively predispose CF patients
to B. bronchiseptica. In addition, our experience suggests that
the incidence of B. bronchiseptica while rare, is higher than
previously reported in non-transplant patients with CF and
approximates Ner's observations [31,35]. Because laboratoryTable 2
Signs and symptoms within one month of first Bordetella bronchiseptica isolate.
Patient Age Increased
cough
Wheeze Shortness of
breath
Crackles Decreased FE
predicted
1 1.9 x NAa
2 4 x NAa
3 8 x
4 12 x x x
5 13 x x x x
6 14 x x x x
7 20 x x
a Patient too young to perform PFTs.isolation and identification of CF microbes can be technically
challenging and difficult, B. bronchiseptica may be
underreported or misidentified. In our experience, the diligence
by our hospital lab resulted in treatment decisions that had a direct
patient benefit.
While the significance of B. bronchiseptica in CF is unclear,
our findings suggest that it may act as both a colonizer and
pathogen. All patients were symptomatic at the initial isolation of
B. bronchiseptica. Although all of our patients had concurrent
growth of MSSA, they also had positive MSSA cultures when
asymptomatic (Table 3). Some patients had persistent colonization
of MSSA following treatment and resolution of symptoms when
B. bronchiseptica did not recur. This suggests that treatment of
B. bronchiseptica resulted in the resolution of symptoms.
On multiple occasions B. bronchiseptica was isolated from
one patient, even when asymptomatic (Table 3). This suggests
that B. bronchiseptica may also act as a colonizer. The potential
of biofilm formation in B. bronchiseptica may explain the
mechanism by which B. bronchiseptica was observed as aV1% Fatigue Increased sputum
production
Decreased
weight
Abnormal chest
x-ray
Chest
pain
x
x x
x x x
x x
Table 3
Patient outcomes after first B. bronchiseptica isolate.
Patient Antibiotic
treatment
Baseline
pre-treatment
FEV1%
predicted
Post
treatment
FEV1%
predicted
Hospitalization Pre-treatment
culture
Post treatment
culture
Number of
subsequent
isolates
Number of
subsequent isolates
when asymptomatic
1 Azithromycin N/A b N/A b No MSSA,
B. bronchiseptica,
Moraxella catarrhalis
MSSA 1 1
2 Cipro N/A b N/A b No B. bronchiseptica,
MSSA,
P. aeruginosa
(matte)
P. aeruginosa
(matte)
0 0
3 Trimethoprim/
sulfamethoxazole
87 92 No B. bronchiseptica,
MSSA, group A
streptococci,
Stenotrophomonas
maltophilia
MSSA 0 0
4 Merropenem Tobramycin 98 97 Yes B. bronchiseptica,
MSSA
MSSA 13 4
5 Ceftazadime Tobramycin
TMP/SMX
79 75 Yes B. bronchiseptica,
P. aeruginosa
(matte),
MSSA
MSSA
Trichosporon
species
0 0
6 Clindamycin Ceftazadime 121 129 Yes B. bronchiseptica,
MSSA, yeast
Staphylococcus sp.,
Stomatococcus sp.,
alpha-hemolytic
streptococci
1 0
7 Clindamycin Ceftazadime
Tobramycin Itraconazole
112 a 115 Yes B. bronchiseptica,
MSSA, yeast
MSSA, yeast 1 0
a Best FEV1% predicted value one year prior and post first B. bronchiseptica culture.
b Patient too young to perform PFTs.
47C. Brady et al. / Journal of Cystic Fibrosis 13 (2014) 43–48chronically colonizing pathogen and the unsuccessful attempts
at eradication. In addition this patient has continued exposure to
unimmunized horses in a boarding environment raising the
likelihood of reinfection.
The pathogenicity of B. bronchiseptica in the CF lung
and the significance of isolation especially as an emerging
pathogen need further examination. As successful therapies
targeting P. aeruginosa improve the care of CF patients and
increase the life spans, other potential pathogens have
emerged. Organisms such as Stenotrophomonas maltophilia,
Alcaligenes xylosoxidans, Ralstonia sp., Burkholderia gladioli
and other Burkholderia spp., Inquilinus limosus and Pandoraea
spp. are increasing in frequency among CF patients [37]. We
recommend the close scrutiny of unusual isolates found in CF
airway cultures particularly gram-negative organisms. Correct
identification of these isolates has value in assessing the clinical
importance of therapies that may benefit the CF patient. Recent
advances in molecular methods have provided better strategies
for accurate identification of unusual CF strains and have become
a useful tool when phenotypic identification fails or is doubtful
[34,35,39,40].
Although commercial phenotypic identification systems
have been validated for the identification of non-fermentative
gram-negative rods, the accuracy is limited or uncertain when
used to identify atypical CF strain [34,39,35]. CF strains often
produce colonies that lack key metabolic characteristics and
have biochemical variability that can cause misidentificationswhen using commercial identification systems. More recently,
strategies using a combination of conventional biochemical tests
and molecular methods (e.g., 16S rRNA sequencing and
MALDI-TOF) for identification of B. bronchiseptica and other
difficult-to-identify CF organisms have allowed for more rapid
and reliable identification results. While the 16S rRNA gene has
been a common target for single pathogen identification,
researchers have now begun to characterize the complete CF
microbial community using next generation sequencing targeting
the same gene [41]. These studies have the potential to provide
new information regarding the pathogenic microbiomes in CF.
While the role of B. bronchiseptica in CF lung disease remains
unclear, the ability to inhibit leukocyte function, interfere with
mucus clearance, and the potential to form biofilms that contribute
to colonization and persistence in the lower respiratory tract may
explain our observations of B. bronchiseptica as a possible
pathogen and colonizer. We encourage routine environmental
histories of all CF patients including the presence of pets, or
domestic farm animals, andB. bronchiseptica immunization status.
We recommend routine B. bronchiseptica immunization of
all domestic mammalian pets and farm animals to reduce the
reservoir for this potential pathogen.
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